All questionsDrug interactions: Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy3 questions · 2 sourcesDrug interactionsWhat drug interactions does Vyndamax have?“Tafamidis inhibits breast cancer resistant protein (BCRP) in humans [see Clinical Pharmacology (12.3)]. Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate.” (opens the source at this quote in a new tab)CopyFlag“CYP3A4 substrates: No clinically significant differences in the pharmacokinetics of midazolam (a CYP3A4 substrate) or on the formation of its active metabolite (1-hydroxymidazolam) were observed when a single 7.5-mg dose of midazolam was administered prior to and after a 14-day regimen of VYNDAQEL 20-mg once daily.” (opens the source at this quote in a new tab)CopyFlag“Cytochrome P450 Enzymes: Tafamidis induces CYP2B6 and CYP3A4 and does not induce CYP1A2. Tafamidis does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4/5 or CYP2D6.” (opens the source at this quote in a new tab)CopyFlag“UDP glucuronosyltransferase (UGT): Tafamidis inhibits intestinal activities of UGT1A1 but neither induces nor inhibits other UDP glucuronosyltransferase (UGT) systemically.” (opens the source at this quote in a new tab)CopyFlagDoes Vyndamax interact with rosuvastatin or methotrexate?“Tafamidis inhibits breast cancer resistant protein (BCRP) in humans [see Clinical Pharmacology (12.3)]. Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate.” (opens the source at this quote in a new tab)CopyFlag“BCRP substrates: Tafamidis inhibits breast cancer resistant protein (BCRP). In a clinical study in healthy participants, AUCinf and Cmax of the BCRP substrate rosuvastatin increased by 96.75% and 85.59%, respectively following multiple doses of VYNDAMAX 61 mg daily dosing.” (opens the source at this quote in a new tab)CopyFlagCan Vyndamax be taken with food?“VYNDAMAX can be taken with or without food.1” (opens the source at this quote in a new tab)CopyFlag“No clinically significant differences in the pharmacokinetics of tafamidis were observed following administration of a high fat, high calorie meal.” (opens the source at this quote in a new tab)CopyFlag